Accordingly, here we performed a systematic review and meta-analysis where we aimed to assess the efficacy of combined treatment of metformin plus PPAR agonists versus metformin treatment alone in improving glycemic control, lipid profile, and adverse events in patients with type 2 diabetes. The gene discussed is PPARA; the disease is type 2 diabetes mellitus.